The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Apparent Advanced Stage Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

被引:49
|
作者
Nezhat, Farr R. [1 ]
DeNoble, Shaghayegh M. [1 ]
Liu, Connie S. [2 ]
Cho, Jennifer E. [1 ]
Brown, Douglas N. [1 ]
Chuang, Linus [3 ]
Gretz, Herbert [3 ]
Saharia, Prakash [4 ]
机构
[1] Columbia Univ, Dept Obstet & Gynecol, Div Gynecol Oncol & Minimally Invas Surg, St Lukes Roosevelt Med Ctr, New York, NY 10019 USA
[2] NYU, Langone Med Ctr, Dept Obstet & Gynecol, New York, NY USA
[3] Mt Sinai Med Ctr, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, New York, NY 10029 USA
[4] Winthrop Univ Hosp, Dept Gen Surg, Mineola, NY 11501 USA
关键词
Laparoscopy; Ovarian Cancer; Cytoreduction; IV EPITHELIAL OVARIAN; CYTOREDUCTIVE SURGERY; SURVIVAL; CARCINOMA; MANAGEMENT; LAPAROTOMY; IMPACT; RATES;
D O I
10.4293/108680810X12785289143990
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives: To describe our experience with laparoscopic primary or interval tumor debulking in patients with presumed advanced ovarian, fallopian tube, or peritoneal cancers. Methods: This is a retrospective analysis of a prospective case series. Women with presumed advanced (FIGO stage IIC or greater) ovarian, fallopian tube, or primary peritoneal cancers deemed appropriate candidates for laparoscopic debulking by the primary surgeon(s) were recruited. Results: The study comprised 32 patients who underwent laparoscopic evaluation. Seventeen underwent total laparoscopic primary or interval cytoreduction, with 88.2% optimal cytoreduction. Eleven underwent diagnostic laparoscopy and conversion to laparotomy for cytoreduction, with 72.7% optimal cytoreduction. Four patients had biopsies, limited cytoreduction, or both. In the laparoscopy group, 9 patients have no evidence of disease (NED), 6 are alive with disease (AWD), and 2 have died of disease (DOD), with mean follow-up time of 19.7 months. In the laparotomy group, 3 patients are NED, 5 are AWD, and 3 are DOD, with mean follow-up of 25.8 months. Estimated blood loss and length of hospital stay were less for the laparoscopy group (P=0.008 and P=0.03), while operating time and complication rates were not different. Median time to recurrence was 31.7 months for the laparoscopy group and 21.5 months for the laparotomy group (P=0.3). Conclusions: Laparoscopy can be used for diagnosis, triage, and debulking of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer and is technically feasible in a well-selected population.
引用
收藏
页码:155 / 168
页数:14
相关论文
共 50 条
  • [41] PATHOLOGIC DISTRIBUTION OF DISEASE DURING INTERVAL DEBULKING VERSUS PRIMARY TUMOR REDUCTION IN PRIMARY PERITONEAL, OVARIAN, OR FALLOPIAN TUBE CARCINOMA
    Previs, R.
    Bailey, C.
    Fellman, B.
    Zaid, T.
    Huang, M.
    Brown, A.
    Ahmed, E.
    Nyla, B.
    Broaddus, R.
    Bodurka, D.
    Sood, A.
    Westin, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 554 - 554
  • [42] LAPAROSCOPIC SURGICAL STAGING FOR APPARENT EARLY STAGE OVARIAN CANCER: A PROPENSITY-MATCHED COMPARISON WITH OPEN SURGICAL STAGING
    Ditto, A.
    Bogani, G.
    Martinelli, F.
    Lorusso, D.
    Chiappa, V.
    Daniele, A.
    Perotto, S.
    Raspagliesi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 428 - 428
  • [43] Validity of the 2014 FIGO Stage IIIA1 Subclassification for Ovarian, Fallopian Tube, and Peritoneal Cancers
    Matsuoka, Ayumu
    Tate, Shinichi
    Nishikimi, Kyoko
    Iwamoto, Masami
    Otsuka, Satoyo
    Shozu, Makio
    IN VIVO, 2022, 36 (05): : 2453 - 2460
  • [44] Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen, K. M.
    Rodriguez, N.
    Horowitz, N. S.
    Campos, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] PATTERNS OF CARE FOR PATIENTS WITH ADVANCED OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER: A RETROSPECTIVE AUDIT
    Lin, E.
    Lo, C.
    Richardson, G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 54 - 54
  • [46] A phase II study of cetuximabpaclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer.
    Aghajanian, C
    Sabbatini, P
    Derosa, F
    Gerst, S
    Spriggs, DR
    Dupont, J
    Hensley, ML
    Pezzulli, S
    Konner, J
    Schilder, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 466S - 466S
  • [47] Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer
    Yoshihama, Tomoko
    Nomura, Hiroyuki
    Iwasa, Naomi
    Kataoka, Fumio
    Hashimoto, Shiho
    Nanki, Yoshiko
    Hirano, Takuro
    Makabe, Takeshi
    Sakai, Kensuke
    Yamagami, Wataru
    Hirasawa, Akira
    Aoki, Daisuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (11) : 1019 - 1023
  • [48] Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities - A systematic review
    Sorensen, Rie D.
    Schnack, Tine H.
    Karlsen, Mona A.
    Hogdall, Claus K.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (03) : 571 - 581
  • [49] Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas, Vasileios D.
    Schiavone, Maria B.
    Kadouri, David
    Zivanovic, Oliver
    Roche, Kara Long
    O'Cearbhaill, Roisin
    Abu-Rustum, Nadeem R.
    Levine, Douglas A.
    Sonoda, Yukio
    Gardner, Ginger J.
    Leitao, Mario M., Jr.
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (01) : 15 - 20
  • [50] Frequency of genetic testing of patients with ovarian, fallopian tube, and primary peritoneal cancers: Quality improvement initiative
    Nawlo, Jude
    Espino, Kevin
    Gerber, Deanna
    Chan, Kent
    Jimenez, Edward
    Chalas, Eva
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S270 - S271